Abstract
BackgroundIrritable bowel syndrome (IBS) is one of the most common functional digestive disorders. Our understanding about its comorbidities, biomarkers, or long-term risks is still incomplete. ObjectiveTo characterize comorbidities and biomarkers for IBS and establish the effect of IBS on overall- and cause specific mortality. MethodsWe analyzed data from the population-based cohort of the UK Biobank (UKB) with 493,974 participants, including self-reported physician-diagnosed (n = 20,603) and ICD-10 diagnosed (n = 7656) IBS patients, with a mean follow-up of 11 years. We performed a phenome-wide association study (PheWAS) and competing risk analysis to characterize common clinical features in IBS patients. ResultsIn PheWAS analyses, 260 PheCodes were significantly overrepresented in self-reported physician-diagnosed IBS patients, 633 in patients with ICD-10 diagnosed IBS (ICD-10-IBS), with 221 (40%) overlapping. In addition to gastrointestinal diseases, psychiatric, musculoskeletal, and endocrine/metabolic disorders represented the most strongly associated PheCodes in IBS patients. Self-reported physician-diagnosed IBS was not associated with increased overall mortality and the risk of death from cancer was decreased (hazard ratio [HR] = 0.78 [95% CI = 0.7-0.9]). Lastly, we evaluated changes in serum metabolites in IBS patients and identified glycoprotein acetyls (GlycA) as a potential biomarker in IBS. One standard deviation increase in GlycA raised the risk of self-reported IBS/ICD-10 coded by 9%-20% (odds ratio [OR] = 1.09 [95% CI = 1.1-1.1]/OR = 1.20 [95% CI = 1.1-1.3]) and the risk of overall mortality in ICD-10-IBS patients by 28% (HR = 1.28 [95% CI = 1.1-1.5]). ConclusionOur large-scale association study determined IBS patients having an increased risk of several different comorbidities and that GlycA was increased in IBS patients.
Original language | English |
---|---|
Pages (from-to) | 458-470 |
Number of pages | 13 |
Journal | United European Gastroenterology Journal |
Volume | 11 |
Issue number | 5 |
Early online date | 1 May 2023 |
DOIs | |
Publication status | Published - Jun 2023 |
Keywords
- biomarkers
- comorbidities
- functional digestive disorders
- glycoprotein acetyls
- irritable bowel syndrome
- mortality
- PheWAS analysis
- FUNCTIONAL GASTROINTESTINAL DISORDERS
- FOLLOW-UP
- PATHWAYS
- PATHOPHYSIOLOGY
- SYMPTOMS
- SURVIVAL
- BRAIN
- GLYCA
- RISK